Jiangxi Synergy Pharmaceutical Co. Ltd. Class A

Jiangxi Synergy Pharmaceutical Co. Ltd. Class A

SSZSE:300636
6.51
CNY
+0.06
(+0.93%)
0.07EPS
106.79P/E
2.98BMarket Cap
Apr 29Next Earn
Jiangxi Synergy Pharmaceutical Co. Ltd. Class A
SZSE:300636
(Shenzhen Stock Exchange)

Recent

price

6.51

P/E

ratio

106.79

div

yld

0.96%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.86
1.16
0.69
1.25
1.09
1.03
0.86
1.33
1.41
1.92
2.21
1.9
1.81
1.97
1.91
Revenue per Share
0.07
0.14
0.13
0.29
0.25
0.23
0.08
0.16
0.23
0.26
0.31
0.28
0.25
0.17
0.07
Basic EPS, GAAP
- -
- -
0.11
- -
0.14
-0.28
-0.54
-0.69
-0.48
-0.95
-0.35
-0.13
0.35
-0.21
- -
Free Cash Flow per Basic Share
0.03
0.07
0.03
0.02
0.01
- -
0.03
0.02
0.07
0.07
0.1
0.07
0.07
0.07
0.06
Dividend per Share
0.37
0.65
0.97
1.07
1.32
2.04
2.11
2.27
2.65
2.88
3.77
5.26
5.48
5.63
5.68
Book Value per Share
0.33
0.6
0.92
1.05
1.29
1.97
2.03
2.2
2.57
2.81
3.71
5.21
5.43
5.59
5.64
Tangible Book Value per Share
122
122
307
220
230
289
309
309
309
309
326
380
420
420
420
Basic Weighted Avg Shares
105
142
213
275
250
297
267
413
435
592
720
722
759
829
801
Sales/Revenue/Turnover
10.28
16.88
23.87
24.58
23.39
24.71
8.39
14.78
20.53
16.77
17.25
16.98
16.19
15.28
9.6
Operating Margin (%)
- -
- -
13
15
20
21
24
43
52
52
67
69
115
131
- -
Depreciation Expense
8
17
39
63
58
65
25
48
70
81
101
106
107
73
28
Net Income, GAAP
9.77
13.45
13.76
13.36
14.1
12.26
6.82
6.53
10.26
8.17
5.16
5.79
7.07
3.29
- -
Effective Tax Rate (%)
7.67
11.93
18.44
22.88
23.19
22.06
9.18
11.7
16.09
13.7
13.98
14.68
14.04
8.82
3.48
Profit Margin (%)
-51
-26
-16
57
125
370
149
193
407
283
183
495
545
795
655
Working Capital
14
22
7
8
25
20
- -
114
366
623
329
252
400
187
52
LT Debt
46
79
118
247
305
637
658
706
817
888
1,320
2,226
2,309
2,365
2,387
Total Equity
- -
9.29
18.1
22.69
15.29
12.5
3.67
6.08
6.1
5.26
5.56
4.3
3.45
2.41
- -
Return on Invested Capital (%)
- -
15.99
23.16
26.53
18.27
12.97
3.67
6.56
6.78
5.59
5.94
4.68
4.11
2.83
- -
Return on Capital (%)
- -
27.16
39.84
34.48
21.04
13.9
3.79
7.08
9.2
9.52
9.12
5.98
4.7
3.13
1.18
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
573
415
129
LT Borrowings
39
38
52
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
420
420
420
Market Capitalization
3,423
2,675
2,977

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,434
1,298
1,051
Cash, Cash Equivalents & STI
274
242
274
Accounts Receivable, Net
126
129
141
Inventories
525
553
544
Total Current Liabilities
788
673
396
Payables & Accruals
- -
- -
- -
ST Debt
573
415
129
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
29.11%
26.44%
2.45%
Free Cash Flow
261.74%
-114.6%
-159.97%
Net Income, GAAP
9.89%
2.87%
-31.42%
Sales/Revenue/Turnover
13.19%
14.43%
9.19%
Total Cash Common Dividend
208.62%
6.76%
-1.16%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
206
176
188
189
759
2025
187
241
- -
192
829
2026
184
199
225
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.06
0.06
0.03
0.25
2025
0.05
0.09
- -
-0.03
0.17
2026
0.04
0.01
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.06
0.02
-0.03
0.07
2025
0.01
0.05
- -
0.01
0.07
2026
0.01
0.05
- -
- -
- -
Business
Jiangxi Synergy Pharmaceutical Co., Ltd. (300636.SZ) manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, raw materials, and fine chemicals worldwide, with core products including gabapentin, candesartan cilexetil, celecoxib, aceclofenac, rebamipide, venlafaxine HCl, azilsartan medoxomil, dabigatran etexilate mesylate, amlodipine besylate, mirabegron, empagliflozin, and intermediates for anticoagulants, antihypertensives, anti-inflammatories, antiepileptics, antidepressants, and antiviral drugs; the company serves domestic and international markets in Europe, North America, Japan, South Korea, and other regions. Founded in 2004 and headquartered in Yichun, Jiangxi Province, China, with manufacturing facilities in Fengxin Industrial Park, it operates in the healthcare sector focusing on drug manufacturers for specialty and generic pharmaceuticals, employing approximately 1,362 people. Recent developments include obtaining South Korean regulatory approval and pharmaceutical registration certificates for amlodipine besylate, azilsartan potassium (Amiasartan potassium), and mirabegron in 2025; achieving GMP compliance certification from Jiangxi authorities for empagliflozin in March 2025; securing European marketing authorization for celecoxib; receiving a patent for a triazine ketone compound in April 2025; and reporting first-quarter 2025 revenue of CNY 187 million despite a year-on-year decline.